About
The tremendous advances in the Precision Medicine field are shifting the focus of treatment towards more precise and targeted treatments, that leverage intrinsic features of the immune system. As the genetic background of the patient and/or disease, determines the efficacy of such therapies, there is a growing need for Companion Diagnostics (CDx) to match the right patients to the right therapy at the right time.
The co-development of a CDx between Pharma and IVD manufacturers comes with its own Grey Zones and Growing Pains, with differing regulations, submission processes and different understanding of the roles and responsibilities. Theses challenges also offer opportunities to improve the ways of working and increase partnership effectivity.
During this webinar, Kirsten van Garsse (QbD group) and Jules Petit discuss key elements of our joint panel discussion at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe and dive deeper into the regulatory impact of current developments and trends in the Companion Diagnostics space.
Recording from April 8, 2026; presented by Kirsten van Garsse, MSc (QbD Group) and Jules Petit, PhD (GenDx).
